InMed Pharmaceuticals Announces ATM Offering Prospectus Filing

InMed Pharmaceuticals ( (INM) ) has issued an announcement.

InMed Pharmaceuticals Inc., a biopharmaceutical company focused on developing and commercializing pharmaceutical products and managing its publicly traded common shares, continues to utilize capital markets instruments as part of its financing strategy. On April 3, 2026, the company filed a prospectus supplement and related prospectus with the U.S. Securities and Exchange Commission for the sale of its common shares under an existing at-the-market offering agreement with H.C. Wainwright & Co., which is supported by an effective shelf registration statement and an accompanying legal opinion on the validity of the shares.

The most recent analyst rating on (INM) stock is a Hold with a $0.62 price target. To see the full list of analyst forecasts on InMed Pharmaceuticals stock, see the INM Stock Forecast page.

Spark’s Take on INM Stock

According to Spark, TipRanks’ AI Analyst, INM is a Neutral.

The score is weighed down primarily by weak financial fundamentals (large ongoing losses and cash burn despite improving revenue) and bearish technicals (below all key moving averages with negative MACD). Corporate events are mixed but include meaningful listing and business-transition risk, while valuation inputs are not meaningful/supportive based on the provided P/E and missing dividend yield.

To see Spark’s full report on INM stock, click here.

More about InMed Pharmaceuticals

InMed Pharmaceuticals Inc. is a biopharmaceutical company, with its activities centered on the development and commercialization of pharmaceutical products. The company’s primary focus is on issuing and managing its common shares as part of its capital markets and financing strategy in the public securities markets.

Average Trading Volume: 117,382

Technical Sentiment Signal: Sell

Current Market Cap: $1.98M

For a thorough assessment of INM stock, go to TipRanks’ Stock Analysis page.